Topical MTH1 Inhibition Suppresses SKP2-WNT5a-Driven Psoriatic Hyperproliferation
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26157174 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Cecilia Bivik Eding und 9 weiteren Autor:innen. Beteiligte Einrichtung: Ingrid Asp Psoriasis Research Center, Department of Biomedical and Clinical Sciences, Linköping University, 581 85 Linköping, Sweden. Hauptthemen laut MEDLINE: Psoriasis, S-Phase Kinase-Associated Proteins, Wnt-5a Protein, Phosphoric Monoester Hydrolases. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ingrid Asp Foundation, the Welander Foundation, the Swedish Psoriasis Association.
Abstract (Originalsprache)
Topically applied TH1579 alleviated the psoriatic phenotype in the imiquimod-induced psoriasis mouse model by decreasing CD45+, Ly6b+, and CD3+ cell infiltration and downregulating the expression of the proliferation marker PCNA. Moreover, TH1579 strongly suppressed IL-17 expression in mouse skin, accompanied by reduced infiltration of IL-17-producing γδ-T cells. Furthermore, TH1579 decreased keratinocyte viability and proliferation. Mass spectrometry data analysis revealed the enrichment of proteins associated with nucleotide excision repair and cell cycle regulation. The key cell cycle regulatory protein F-box protein S-phase kinase-associated protein 2 (SKP2) was significantly downregulated, along with the psoriasis-associated proliferation marker WNT5a, identified as a SKP2 downstream target. The downregulation of SKP2 and WNT5a was confirmed in MTH1i-treated mouse skin. Our findings support the topical administration of MTH1i TH1579 as a psoriasis treatment. The therapeutic effects depended on the SKP2/WNT5a pathway, which mediates psoriatic hyperproliferation. This study introduces a conceptually innovative topical treatment for psoriasis patients with mild-to-moderate disease who have limited therapeutic options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ingrid Asp Psoriasis Research Center, Department of Biomedical and Clinical Sciences, Linköping University, 581 85 Linköping, Sweden.
- Clinical Genomics Linköping, SciLife Laboratory, Department of Biomedical and Clinical Sciences, Linköping University, 581 85 Linköping, Sweden.
- Oxcia AB, 113 34 Stockholm, Sweden.
- Department of Oncology and Pathology, Karolinska Institute, 171 77 Stockholm, Sweden.
ORCID-Profile: Cecilia Bivik Eding, Ines Köhler, Lavanya Moparthi, Blanka Andersson, Debojyoti Das, Charlotta Enerbäck
Förderung
- Ingrid Asp Foundation
- the Welander Foundation
- the Swedish Psoriasis Association
- ALF Grants, Region Östergötland
Zitieren
APA
Bivik Eding, C., Köhler, I., Moparthi, L., Sjögren, F., Andersson, B., Das, D., Verma, D., Scobie, M., Warpman Berglund, U., & Enerbäck, C. (2025). Topical MTH1 Inhibition Suppresses SKP2-WNT5a-Driven Psoriatic Hyperproliferation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157174
Vancouver
Bivik Eding C, Köhler I, Moparthi L, Sjögren F, Andersson B, Das D, et al. Topical MTH1 Inhibition Suppresses SKP2-WNT5a-Driven Psoriatic Hyperproliferation. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157174
BibTeX
@article{BivikEding2025,
author = {Bivik Eding, Cecilia and Köhler, Ines and Moparthi, Lavanya and Sjögren, Florence and Andersson, Blanka and Das, Debojyoti and Verma, Deepti and Scobie, Martin and Warpman Berglund, Ulrika and Enerbäck, Charlotta},
title = {Topical MTH1 Inhibition Suppresses SKP2-WNT5a-Driven Psoriatic Hyperproliferation},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26157174}
}
EUVIMED